An update from Avalo Therapeutics (AVTX) is now available.
At the 2024 Annual Meeting of the Company, a significant 58% of shareholders participated, either in person or by proxy. They elected seven board members to serve until the next annual meeting, approved the issuance of common stock for various purposes under Nasdaq Rule 5635, and endorsed amendments to equity incentive and employee stock purchase plans. Shareholders also ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year. Each proposal passed with a strong majority, demonstrating shareholder confidence in the Company’s governance and strategic direction.
Learn more about AVTX stock on TipRanks’ Stock Analysis page.
